| Document |
Document Title |
|
WO/2015/125085A1 |
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are G...
|
|
WO/2015/127161A1 |
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.
|
|
WO/2015/125710A1 |
The present invention addresses the problem of providing a novel method for producing a compound that can act as an FXa inhibitor, a salt of the compound or a hydrate of the compound or the salt. The solution for the problem is a method ...
|
|
WO/2015/123230A1 |
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions cont...
|
|
WO2015122321A1 |
Provided are: a polymer compound for providing an organic semiconductor material exhibiting excellent conversion efficiency; a starting-material compound having high material design freedom; and methods for producing the same. This polym...
|
|
WO/2015/121336A1 |
The present invention relates to polymers comprising as monomer units one or more compounds having at least a triazine or a pyrimidine core. Preferably, the polymer of the present invention comprises as monomer unit the compound of formu...
|
|
WO/2015/123385A1 |
Described herein are modified sugar, iminosugar and azasugar compounds and methods of making same. One or more of these modified compounds contain sulfates, sulfites, sulfamates and/or sulfonamides. Also described are pharmaceutical comp...
|
|
WO/2015/120730A1 |
Disclosed are a series of novel thiochromeno[2,3-c]quinolin-12-one derivatives, and also provided are a preparation method for the derivatives and an application of the derivatives. The application comprises preparing said derivatives in...
|
|
WO/2015/115650A1 |
Provided is a method for producing an optically active carboxylic acid ester at a high yield and with high enantioselectivity using dynamic kinetic resolution, said optically active carboxylic acid ester having an α-nitrogen substituent...
|
|
WO/2015/114660A1 |
The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceu...
|
|
WO/2015/114317A1 |
This invention relates to antibacterial drug compounds of formula (I) containing a fused isothiazolinone or pyrazolone ring and related compounds. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also re...
|
|
WO/2015/105195A1 |
Provided are a compound indicated by general formula (I), a tautomer of said compound, a stereoisomer, or a pharmacologically acceptable salt thereof or a solvate of these, and a drug for the treatment of pulmonary hypertension that has ...
|
|
WO/2015/091945A1 |
Compounds of the formula (I) and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, including all stereoisomers and tautomeric forms, and wherein the substituents are as defined in...
|
|
WO/2015/091584A1 |
Provided are thiazolopyridine compounds that are inhibitors of TYK2 kinase, compositions containing these compounds and methods for treating diseases mediated by TYK2 kinase. In particular, provided are compounds of Formula (I), (II) or ...
|
|
WO/2015/091595A1 |
The present invention provides a compound of formula I' having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...
|
|
WO/2015/089327A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
|
|
WO/2015/089337A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
|
|
WO/2015/086504A1 |
A series of substituted imidazo[2,1-b]thiazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoim...
|
|
WO/2015/079459A1 |
Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmac...
|
|
WO/2015/078799A1 |
The present invention relates to chemical compounds of general formula (I), in which Z, Y1, Y2, Y3, R3, R4, R5, R6, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transpo...
|
|
WO/2015/075023A1 |
The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceutical...
|
|
WO/2015/075025A1 |
The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, ...
|
|
WO/2015/068773A1 |
Provided is an agricultural and horticultural fungicide manifesting a high control effect against a wide range of plant pathogens. The present invention is a compound represented by formula (I) or a salt thereof, an agricultural and hort...
|
|
WO/2015/060183A1 |
A polymeric compound according to the present invention contains a benzobisthiazole structure unit represented by general formula (1). [In general formula (1), A1 and A2 independently represent an alkoxy group, a thioalkoxy group, a thio...
|
|
WO/2015/054283A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store -operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alon...
|
|
WO/2015/052226A1 |
The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.
|
|
WO/2015/052103A1 |
Pesticidally active N-iminopyridinium ylide compounds of formula (I) wherein A is CR4R5 or C=O; X is O or S; Y is O or S; Het is a 5- or 6-membered carbon-bound saturated, unsaturated or aromatic heterocycle, having 1, 2 or 3 heteroatoms...
|
|
WO/2015/054089A1 |
This invention relates to a compounds of formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
WO/2015/049369A1 |
The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents ar...
|
|
WO/2015/050212A1 |
[Problem] The present invention addresses the problem of providing novel compounds that have T-type voltage-gated calcium channel-blocking activity and are useful particularly in treating pain, chronic kidney disease, and atrial fibrilla...
|
|
WO/2015/050472A1 |
The invention relates to fused indole compounds of formula (I) that can be used for treating microbial infections, in particular, fungal infections, and selectively kill cancer cells.
|
|
WO/2015/046193A1 |
The present invention relates to a compound represented by formula (I) (In the formula, R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, etc., X is -N(R2)-, -O- or -S-, Y...
|
|
WO/2015/047124A1 |
The present invention relates to a treatment for allergic, autoimmune, oncological and other diseases using novel families of chemical compounds which exhibit enhanced efficacy in the inhibition of Syk kinase, mutant forms thereof and al...
|
|
WO/2015/043492A1 |
Provided herein are substituted urea derivatives or stereoisomers, geometric isomers, tautomers, N-oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions th...
|
|
WO/2015/046480A1 |
A tetrazolinone compound represented by formula (1) (In the formula: Q is (In the formula, R21, R22, R23, R24, and R27 are a hydrogen atom, etc.), etc.; R1 and R2 are each a hydrogen atom, etc.; R3 is a C1 to C6 alkyl group, etc. which m...
|
|
WO/2015/044075A1 |
The present invention relates to compounds of formula I wherein Y is N or C-R1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with dif...
|
|
WO/2015/043364A1 |
The present invention relates to a novel compound of formula (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein R1 represents a substituted or unsubstituted aryl or heteroaryl; R2 represents an opti...
|
|
WO/2015/041026A1 |
The present invention pertains to a benzobis (thiadiazole) derivative represented by general formula (1). (In the formula: R1 represents a straight-chain or branched alkyl group, or any of the groups represented by formula (2); R2 repres...
|
|
WO/2015/036058A1 |
The present invention relates to fungicidal pyrimidine compounds I, to their use and to methods for combating phytopathogenic fungi. The present invention also relates to mixtures and compositions comprising compounds I and to seed treat...
|
|
WO/2015/038503A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also disclosed are compositions containing the co...
|
|
WO/2015/025025A1 |
The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and dis...
|
|
WO/2015/016343A1 |
This organic transistor uses a compound that, when used in an active semiconductor layer of an organic transistor, exhibits high carrier mobility, little threshold-voltage variation after being driven repeatedly, and a high degree of sol...
|
|
WO/2015/017407A1 |
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A4, A5, A6, A8, R1, R2, R3, R7and n of Formula I, indep...
|
|
WO/2015/011082A1 |
Disclosed are compounds of formula (I) which possess nematicidal properties (I), wherein the structural elements have the meaning as indicated in the description.
|
|
WO/2015/012210A1 |
A compound represented by general formula (I) or a salt thereof. [In the formula, the ring Z represents a 5- to 6-membered heteroaromatic ring having 1 to 2 hetero atoms in the ring; X1 represents a hydrogen atom, a hydroxy group, a hydr...
|
|
WO/2015/010641A1 |
Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1,R2,R3,R5,R6 and L are as defined in the description. Such compounds are suitable for the ...
|
|
WO/2015/012332A1 |
The present invention provides a therapeutic agent or a preventive agent for ophthalmic diseases caused by ocular neovascularization, the agent comprising as an active ingredient a morpholine compound represented by general formula (1) (...
|
|
WO/2015/004481A1 |
The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb. X, W, Y and t are as defined i...
|
|
WO/2015/001076A1 |
The present invention relates to a class of novel isothiazolo[4,3-b]pyridine derivatives and a method for their preparation, as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives ...
|
|
WO/2014/210087A1 |
Disclosed are compounds of Formula (I); and salts thereof, wherein:Formula (II); Q is: R1 is -C(CH3)2OH, -NHC(=0)C(CH3)3, -N(CH3)2, or -CH2Rd; R2 is CI or -CH3; R3 is H, F, or -CH3; Ra is H or -CH3; Rb is H, F, CI, or -OCH3 Rc is H or F;...
|
